The Trump-Pharma Deals Reflect the Flaws of State Capitalism
This essay is a part of The Right Way Forward, Restoring America’s new think tank debate series in which leading conservative institutions argue the defining questions of the post-Trump era. Read about the series here.
TL;DR
- The Trump administration has increased its focus on "state capitalism," implementing discretionary and unpredictable policies to achieve public objectives in the commercial sector.
- Deals with 17 biopharma companies on product pricing and domestic manufacturing exemplify this approach, with officials claiming validation while critics point to problematic methods and secrecy.
- The "most favored nation" (MFN) policy aims to prevent US companies from charging higher prices domestically than in other high-income countries, a position resonating with consumers.
- The administration is asserting authority to dictate private market pricing without explicit congressional authorization, using threats like tariffs to compel company agreement.
- The confidentiality of these deals prevents evaluation of their benefits to consumers, potential for raising prices abroad, or favoring certain companies.
- Concerns exist regarding the compromise of investors' property rights due to arbitrary government actions and the potential for policy reversal after the administration's term.
- The author argues that while downward pressure on drug prices is a valid goal, the administration's methods undermine the rule of law and principles of market function.